'Cutting edge' nonmelanoma research branches three ways

Dallas - Activation of the immune system may prove to be an importanttherapeutic adjuvant in the treatment of nonmelanoma skin cancers in difficultto treat regions, in those that have a high potential to recur, or in individualsfor whom surgery is not possible, Russell P. Hall, III, M.D., said at theannual meeting of the American College of Mohs Micrographic Surgery andCutaneous Oncology.

Related Videos
Related Content

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

EON Gains FDA Clearance for Back and Thighs

March 29th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023
© 2023 MJH Life Sciences

All rights reserved.